Investigation of anti-htlv-i/ii seroprevalence in healthy blood donors in Izmir region, Turkey;Izmir bölgesinde saglikli kan verícílerínde antí-HTLV-I/II seroprevalansinin araçtirilmasi

Mikrobiyoloji Bulteni

Volumn 44, Issue 4, 2010, Pages 579-584

  Sertöz, Ruchan ^a   Turhan, Ajda ^a   Bozkurt, Hale ^a   Çamlioglu, Pinar ^a   Deǧrmenci, Aysu ^a   Aydinok, Yȩim ^a   Erensoy, Selda ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Blood donors; HTLV I II; Seroprevalence; Turkey

Indexed keywords

HUMAN T CELL LEUKEMIA VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD; BLOOD DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGY; FEMALE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MALE; MANDATORY TESTING; STATISTICS; TURKEY (REPUBLIC);

ADULT; BLOOD DONORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HTLV-II ANTIBODIES; HTLV-II INFECTIONS; HUMANS; MALE; MANDATORY TESTING; SEROEPIDEMIOLOGIC STUDIES; TURKEY;

EID: 78649250183     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Edlich RF, Arnette JA, Williams FM. Global epidemic of human T-cell lymphotropic virus type-I (HTLV-I). J Emerg Med 2000; 18: 109-19.
2. Rasulee A, Le Riverend E, Shih J, et al. HTLV-I seroprevalence in blood donors in Cuba. Int J Cancer 1993; 54: 885-6.
3. Levine PH, Blattner WA, Clark J, et al. Geographic distribution of HTLV-I and identification of a new highrisk population. Int J Cancer 1988; 42: 7-12.
4. Williams CK, Dada A, Blattner WA. Some epidemiological features of the human T-cell lymphotropic virus type I (HTLV-I) and ATL in Nigerians. Leukemia 1994; 8(Suppl 1): 77-82.
5. Blattner WA, Nomura A, Clark JW, et al. Modes of transmission and evidence for viral latency from studies of human T-cell lymphotrophic virus type I in Japanese migrant populations in Hawaii. Proc Natl Acad Sci USA 1986; 83: 4895-8.
6. Arif M, Ramia S. Seroprevalence of human T-lymphotropic virus type I (HTLV-I) in Saudi Arabia. Ann Trop Med Parasitol 1998; 92: 305-9.
7. Constantine NT, Fathi Sheba M, Corwin AL, Danahy RS, Callahan JD, Watts DM. A serosurvey for HTLV-I among high-risk populations and normal adults in Egypt. Epidemiol Infect 1991; 107: 429-33.
8. Al-Mufti S, Voevodin A, Ahmed S, Al-Hamdan S, Al-Bisher AA. Prevalence of human T-cell lymphotropic virus type I infection among volunteer blood donors in Kuwait. J Acquir Immune Defic Syndr Hum Retroviral 1997; 15: 88-90.
9. Knox-Macaulay H, McDonald R, al-Busaidy S, Ali N. HTLV-I seroprevalence in the Sultanate of Oman. Scand J Infect Dis 1997; 29: 217-8.
10. Muchinick G, Bouzas MB, Zapiola I, et al. HTLV-I and HTLV-II infection in Uruguay. J Acquir Immune Defic Syndr Hum Retroviral 1992; 5: 743-4.
11. . Vassquez P, Sanchez G, Volante C, et al. Human T-lymphotropic virus type I: new risk for Chilean population. Blood 1991; 78: 850-1.
12. Hurtado L, Gomez L, Andrada R, et al. HTLV-I infection and diseases in Bolivian population. Eighth International Conference on Human Retrovirology: HTLV. June 9-13, 1997. Rio de Janeiro, Brazil.
13. Tokudome S, Tokunaga O, Shimamoto Y, et al. Incidence of adult T-cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. Cancer Res 1989; 49: 226-8.
14. Gessain A, Barin F, Vermant JC, et al. Antibodies to human T-lymphotropic virus type I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407-10.
15. Mochizuki M, Watanabe T, Yamaguchi K, et al. Uveitis associated with human T-cell lymphotropic virus type I. Am J Ophthalmol 1992; 114: 123-9.
16. Namen-Lopes MS, Martins ML, Drummond PC, Lobato RR. Interdisciplinary HTLV Research Group (GIPH), Carneiro-Proietti AB. Lookback study of HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil. Transfus Med 2009; 19: 180-8.
17. Beilke MA. Hematologic hints of HTLV-2 in US blood donors. Blood 2008; 15: 3919-20.
18. Vrielink H, Reesink HW. HTLV-I/II prevalence in different geographic locations. Transfus Med Rev 2004; 18: 46-57.
19. Centers for Disease Control and Prevention and the USPHS Working Group. Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type Il (HTLV-II). Ann Int Med 1993; 118: 448-54.
20. Nelson KE, Donahue JG, Munoz A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery: a multicenter study of HIV-I and HTLV-I/II infections. Ann Intern Med 1992; 117: 554-9.
21. Laperche S, Worms B, Pillonel J. European Network of Transfusion Medicine Societies; Steering Committee. Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009; 96: 104-10.
22. Yenen OS. Saglikli kan vericilerinde ve çeitli hasta gruplannda anti-HTLV-I seroprevalansi. Turk Mikrobiol Cem Derg 1988; 18: 47-58.
23. Yenen OS, Beyazyürek M, Keskin K, et al. Damar ici ilaç kullananlarda HBsAg, anti-HBc, anti-HCV, anti-HTLVI, anti-HIV1/2 görülme sikligi. Klimik Derg 1993; 6: 35-6.
24. Yazan Sertoz R, Erensoy S, Ozçam H, et al. Anti-HTLV-I/II seroprevalence in healthy blood donors in Izmir, Turkey. Turk J Haematol 2003; 20: 81-3.
25. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24: 6058-68.
26. Chiavetta JA, Escobar M, Newman A, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1999-2000. Can Med Assoc J 2003; 169: 767-73.
27. Stigum H, Magnus P, Samdal HH, Nord E. Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model. Int J Epidemiol 2000; 29: 1076-84.
28. Tseliou PM, Spanakis N, Spiliotakara A, Politis C, Legakis NJ, Tsakris A. HTLV-I and Il in southwestern Greece. Transfusion 2003; 43: 1641-2.
29. Taylor GP. The epidemiology of HTLV-I in Europe. J Acquir Immune Defic Syndr Hum Retroviral 1996; 13 (Suppl1):8-14.